Tango Therapeutics, Inc. SEC filings TNGX
Tango Therapeutics, Inc. has 424 filings in SEC EDGAR's recent list, going back to Jul 30, 2020. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K/A |
Amended current report
Officer or director change, Regulation FD disclosure
|
Aug 7, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 6, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 23, 2026 | Jun 19, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 10, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 8, 2026 | Jun 8, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
May 13, 2026 | May 13, 2026 |
| 8-K |
Current report
Officer or director change
|
May 8, 2026 | May 7, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 15, 2026 | Apr 10, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change, Regulation FD disclosure
|
Jan 8, 2026 | Jan 7, 2026 |
| 8-K |
Current report
Officer or director change
|
Jan 5, 2026 | Jan 2, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Nov 21, 2025 | Nov 18, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2025 | Nov 4, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 24, 2025 | Oct 23, 2025 |
| 8-K |
Current report
Results of operations, Other events
|
Oct 23, 2025 | Oct 23, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 25, 2025 | Aug 21, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2025 | Aug 5, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 6, 2025 | Jun 5, 2025 |
| 8-K |
Current report
Results of operations
|
May 12, 2025 | May 12, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2025 | Aug 10, 2022 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jan 13, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 6, 2024 | Nov 6, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2024 | Aug 7, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 6, 2024 | Jun 5, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 23, 2024 | May 23, 2024 |
| 8-K |
Current report
Results of operations
|
May 8, 2024 | May 8, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 18, 2024 | Mar 18, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 7, 2024 | Feb 7, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 8, 2023 | Nov 8, 2023 |
| 8-K |
Current report
Officer or director change
|
Aug 30, 2023 | Aug 28, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 7, 2023 | Aug 3, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 7, 2023 | Jun 6, 2023 |
| 8-K |
Current report
Results of operations
|
May 9, 2023 | May 9, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2023 | Mar 27, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Feb 28, 2023 | Feb 27, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2022 | Aug 10, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2022 | Jun 8, 2022 |
| 8-K |
Current report
Results of operations
|
May 11, 2022 | May 11, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 28, 2022 | Mar 28, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2021 | Nov 9, 2021 |
| 8-K |
Current report
Acquisition or sale of assets, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Aug 13, 2021 | Aug 10, 2021 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Apr 14, 2021 | Apr 13, 2021 |
| 8-K |
Current report
Officer or director change
|
Oct 7, 2020 | Oct 6, 2020 |
| 8-K |
Current report
Other events
|
Sep 14, 2020 | Sep 8, 2020 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change, Other events
|
Sep 9, 2020 | Sep 2, 2020 |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TNGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1819133
- Former names
- BCTG Acquisition Corp. (until Aug 9, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.